We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Unpleasant land

9 August 2017 By Robert Cyran

The business of selling knockoff pills is suffering as regulators pull down barriers, competition mounts and buyers demand big discounts. The toxic mix of falling prices and piles of debt already hurt Mylan, Valeant and Teva. Their latest earnings show the hangover enduring.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)